Vaxxinity, Inc. (NASDAQ: VAXX) is a clinical-stage biotechnology company focused on the development of peptide-based vaccines for serious diseases. Leveraging its proprietary synthetic peptide vaccine platform, the company designs antigens that co-present B-cell and T-cell epitopes to elicit robust and durable immune responses. Vaxxinity’s manufacturing collaborations support clinical-scale production and aim to facilitate broader commercial supply.
The company’s lead clinical programs include UB-311, an active immunotherapeutic vaccine candidate for Alzheimer’s disease currently in mid-stage trials, and UB-612, a multitope vaccine candidate for SARS-CoV-2 intended as a next-generation COVID-19 booster. Beyond these focal assets, Vaxxinity’s pipeline encompasses additional peptide vaccine candidates in preclinical development for oncology and other therapeutic areas, reflecting a strategic emphasis on both neurodegenerative and infectious disease indications.
Headquartered in the Dallas–Fort Worth area, Vaxxinity maintains research and development operations extending into Asia, where it collaborates with academic institutions and contract development organizations. These partnerships provide access to specialized expertise and manufacturing infrastructure, supporting the company’s efforts to advance its vaccine candidates through late-stage clinical evaluation and toward regulatory submission.
Under the leadership of Founder and Chief Executive Officer Frank Lee, PhD, Vaxxinity’s management team combines deep experience in immunology, vaccine development and global commercialization. The company is dedicated to translating its platform technology into differentiated vaccine therapies with the potential to address significant unmet medical needs worldwide.
AI Generated. May Contain Errors.
